Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients

Xi Chen, Liangjie Fang, Yan‐Ping Zhu, Zhang Bao, Qing Wang, Rong Liu, Wenjia Sun, Haiwei Du, Jing Lin, Bing Yu, Songan Chen, Jianya Zhou, Jianying Zhou, Jianying Zhou, Jianying Zhou